The palliative treatment with intrapleural streptokinase in patients with multiloculated malignant pleural effusion: a double-blind, placebo-controlled, randomized study. 2015

Ozkan Saydam, and Kemal Karapinar, and Mertol Gokce, and Lutfiye Kilic, and Muzaffer Metin, and Ibrahim Ilker Oz, and Ozgur Tanriverdi
Thoracic Surgery Department, Yedikule Teaching Hospital for Chest Diseases and Thoracic Surgery, Istanbul, Turkey.

Expansion of the lung is necessary for successful pleurodesis therapy in patients with malignant pleural effusion (MPE). However, this is often impossible in multiloculated MPEs. The aim of this study was to investigate the effect of the fibrinolytic agent, streptokinase, on pleurodesis therapy used in the management of multiloculated MPE. Forty patients with multiloculated MPEs were randomly assigned to two groups: fibrinolytic and control. In the fibrinolytic group, 250,000 IU of streptokinase in 50 ml saline was applied into the pleural space at 24-36-48-60 h after opening a tube thoracostomy. In the control group, the same procedure was carried out using only 50 ml saline solution. Both groups were compared based on the following: (1) volume of pleural drainage at 24-48, 48-72, and 24-72 h, (2) chest computer tomography images before and after therapy, (3) dyspnea symptoms after therapy, and (4) recurrence rate. The mean drainage volumes for the fibrinolytic and control groups were 493 and 248 cc at 24-48 h, 446 and 198 cc at 48-72 h, and 939 and 446 cc at 24-72 h (P < 0.001). Comparison of the two groups by computer tomography revealed that 17 patients (85 %) in the fibrinolytic group had greater than 40 % improvement, whereas only 7 patients (35 %) in the control group had the same degree of improvement (P = 0.001). The dyspnea symptoms disappeared in 90 % of the patients in the fibrinolytic group and in 55 % of the patients in the control group (P = 0.03). Recurrence rate was 11 % in fibrinolytic group and 45 % in control group (P = 0.07). Streptokinase is a reliable treatment option in obtaining effective pleural drainage and increasing lung expansion in patients with multiloculated MPE.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010166 Palliative Care Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed) Palliative Treatment,Palliative Supportive Care,Palliative Surgery,Palliative Therapy,Surgery, Palliative,Therapy, Palliative,Care, Palliative,Palliative Treatments,Supportive Care, Palliative,Treatment, Palliative,Treatments, Palliative
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004322 Drainage The removal of fluids or discharges from the body, such as from a wound, sore, or cavity.
D005260 Female Females
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Ozkan Saydam, and Kemal Karapinar, and Mertol Gokce, and Lutfiye Kilic, and Muzaffer Metin, and Ibrahim Ilker Oz, and Ozgur Tanriverdi
January 2004, The Indian journal of chest diseases & allied sciences,
Ozkan Saydam, and Kemal Karapinar, and Mertol Gokce, and Lutfiye Kilic, and Muzaffer Metin, and Ibrahim Ilker Oz, and Ozgur Tanriverdi
March 1999, Chest,
Ozkan Saydam, and Kemal Karapinar, and Mertol Gokce, and Lutfiye Kilic, and Muzaffer Metin, and Ibrahim Ilker Oz, and Ozgur Tanriverdi
March 2003, Chest,
Ozkan Saydam, and Kemal Karapinar, and Mertol Gokce, and Lutfiye Kilic, and Muzaffer Metin, and Ibrahim Ilker Oz, and Ozgur Tanriverdi
October 1996, The Thoracic and cardiovascular surgeon,
Ozkan Saydam, and Kemal Karapinar, and Mertol Gokce, and Lutfiye Kilic, and Muzaffer Metin, and Ibrahim Ilker Oz, and Ozgur Tanriverdi
March 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
Ozkan Saydam, and Kemal Karapinar, and Mertol Gokce, and Lutfiye Kilic, and Muzaffer Metin, and Ibrahim Ilker Oz, and Ozgur Tanriverdi
August 2022, Cureus,
Ozkan Saydam, and Kemal Karapinar, and Mertol Gokce, and Lutfiye Kilic, and Muzaffer Metin, and Ibrahim Ilker Oz, and Ozgur Tanriverdi
February 2004, Chest,
Ozkan Saydam, and Kemal Karapinar, and Mertol Gokce, and Lutfiye Kilic, and Muzaffer Metin, and Ibrahim Ilker Oz, and Ozgur Tanriverdi
June 2011, Asian cardiovascular & thoracic annals,
Ozkan Saydam, and Kemal Karapinar, and Mertol Gokce, and Lutfiye Kilic, and Muzaffer Metin, and Ibrahim Ilker Oz, and Ozgur Tanriverdi
February 1998, The Journal of the Association of Physicians of India,
Ozkan Saydam, and Kemal Karapinar, and Mertol Gokce, and Lutfiye Kilic, and Muzaffer Metin, and Ibrahim Ilker Oz, and Ozgur Tanriverdi
February 2012, Cancer investigation,
Copied contents to your clipboard!